BMRA Stock Overview
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.82|
|52 Week High||US$7.38|
|52 Week Low||US$2.65|
|1 Month Change||-36.91%|
|3 Month Change||-36.49%|
|1 Year Change||-17.78%|
|3 Year Change||26.16%|
|5 Year Change||8.07%|
|Change since IPO||-19.43%|
Recent News & Updates
Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Despite strong share price growth of 66% for Biomerica, Inc. ( NASDAQ:BMRA ) over the last few years, earnings growth...
|BMRA||US Medical Equipment||US Market|
Return vs Industry: BMRA underperformed the US Medical Equipment industry which returned -15.6% over the past year.
Return vs Market: BMRA underperformed the US Market which returned -10.4% over the past year.
|BMRA Average Weekly Movement||9.3%|
|Medical Equipment Industry Average Movement||10.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: BMRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BMRA's weekly volatility (9%) has been stable over the past year.
About the Company
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient’s body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
Biomerica Fundamentals Summary
|BMRA fundamental statistics|
Is BMRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BMRA income statement (TTM)|
|Cost of Revenue||US$12.12m|
Last Reported Earnings
Feb 28, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.27|
|Net Profit Margin||-23.98%|
How did BMRA perform over the long term?See historical performance and comparison
Is Biomerica undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMRA ($2.82) is trading below our estimate of fair value ($13.34)
Significantly Below Fair Value: BMRA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMRA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: BMRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMRA is overvalued based on its PB Ratio (3.7x) compared to the US Medical Equipment industry average (2.5x).
How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Biomerica performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMRA is currently unprofitable.
Growing Profit Margin: BMRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.4%).
Return on Equity
High ROE: BMRA has a negative Return on Equity (-35.93%), as it is currently unprofitable.
How is Biomerica's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BMRA's short term assets ($15.2M) exceed its short term liabilities ($6.7M).
Long Term Liabilities: BMRA's short term assets ($15.2M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: BMRA is debt free.
Reducing Debt: BMRA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BMRA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BMRA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 28.3% per year.
What is Biomerica current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BMRA has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Zack Irani (55 yo)
Mr. Zackary S. Irani, also known as Zack, has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President an...
CEO Compensation Analysis
Compensation vs Market: Zack's total compensation ($USD488.33K) is below average for companies of similar size in the US market ($USD770.21K).
Compensation vs Earnings: Zack's compensation has increased whilst the company is unprofitable.
Experienced Management: BMRA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: BMRA's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Biomerica, Inc.'s employee growth, exchange listings and data sources
- Name: Biomerica, Inc.
- Ticker: BMRA
- Exchange: NasdaqCM
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$38.720m
- Shares outstanding: 12.85m
- Website: https://www.biomerica.com
Number of Employees
- Biomerica, Inc.
- 17571 Von Karman Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.